K143690 is an FDA 510(k) clearance for the Ekso™ (version 1.1) and Ekso GT™ (version 1.2). Classified as Powered Exoskeleton (product code PHL), Class II - Special Controls.
Submitted by Ekso Bionics, Inc. (Richmond, US). The FDA issued a Cleared decision on April 1, 2016 after a review of 464 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Neurology FDA review panel, regulated under 21 CFR 890.3480 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Neurology submissions.
View all Ekso Bionics, Inc. devices